Cogent “intends to use the net proceeds from the offering for continued development, regulatory and commercial preparation activities relating to bezuclastinib and other product candidates, activities to support the planned commercial launch of bezuclastinib, as well as for working capital and general corporate purposes. J.P. Morgan, Leerink Partners and Guggenheim Securities are acting as joint book-running managers for the offering. LifeSci Capital is also acting as lead manager for the offering.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on COGT:
- Cogent Biosciences price target raised to $22 from $12 at H.C. Wainwright
- Cogent Biosciences price target raised to $9 from $7 at Baird
- Promising Outlook for Cogent Biosciences: Bezuclastinib’s Potential in Systemic Mastocytosis and Beyond
- Cogent Biosciences Receives Buy Rating on Promising Trial Results and Market Potential
- Musk to launch new political party, Trump threatens BRICS tariff: Morning Buzz